ArticleBeilstein journal of nanotechnology2025
Missing links in nanomaterials research impacting productivity and perceptions.
Article in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next generation graphene based MXene metamaterial multicylinder resonator solar absorber optimized with machine learning for conceptual solar dryer mining applications.Discover nano · 2026Article
- Advances in the Control of Plant Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein we point out critical yet often overlooked barriers restraining the real-world impact and commercial viability of nanomaterials research. In spite of decades of scientific progress, nanotechnology remains underutilized in public-facing applications. A major issue is the limited engagement of leading tech industries in developing nanotechnology-based products, prompting concerns about tangible societal and industrial outcomes. Far away, funding challenges, the field is hindered by fragmented regulations, ambiguous safety guidelines designed for bulk materials, and the absence of globally harmonized standards. These systemic limitations, coupled with persistent misconceptions, have stalled translation from lab to market. In contrast to numerous productive technologies like generative AI, machine learning, and related progress, nanotechnology has not achieved autonomous societal integration. The author argues that without a unified, transparent, and science-driven global regulatory framework, the transformative potential of nanotechnology will remain unrealized, despite over decades of excellent discoveries. This perspective calls for carefully considerations linked to productivity perception, true funding utility, and foundational reform to unlock nanotechnology's full promise across sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.